How should vaginal bleeding be managed in a woman taking anticoagulant therapy (e.g., warfarin, direct oral anticoagulants)?

Management of Vaginal Bleeding in Women Taking Anticoagulants

Stop the anticoagulant immediately if the bleeding is major (hemodynamic instability, hemoglobin drop ≥2 g/dL, or requires ≥2 units RBCs transfusion), initiate local bleeding control measures, and consider reversal agents for life-threatening hemorrhage. 1

Assess Bleeding Severity First

Determine if the vaginal bleeding qualifies as major or non-major using these criteria 1:

Major Bleeding Criteria (any one):

• Hemodynamic instability
• Hemoglobin decrease ≥2 g/dL
• Requires transfusion of ≥2 units RBCs
• Bleeding at a critical site

Non-Major Bleeding:

• Does not meet above criteria
• Clinically significant but stable

Immediate Management Algorithm

For Major Vaginal Bleeding:

Stop the anticoagulant immediately 1

1. Initiate bleeding control:

   • Local therapy/manual compression
   • Volume resuscitation and supportive care
   • Assess for comorbidities (thrombocytopenia, uremia, liver disease)
   • Consider gynecologic procedural management 1

2. For Warfarin users:

   • Give 5-10 mg IV vitamin K immediately 1
   • Administer 4-factor prothrombin complex concentrate (4F-PCC) for life-threatening bleeding 1:
     • INR 2 to <4: 25 units/kg
     • INR 4-6: 35 units/kg
     • INR >6: 50 units/kg

3. For DOAC users with life-threatening bleeding 1:

   • Dabigatran: Give 5g idarucizumab IV (if unavailable, use PCC or aPCC)
   • Apixaban/Rivaroxaban: Give andexanet alfa (dosing based on timing and dose of last DOAC intake)
   • Edoxaban/Betrixaban: Use high-dose andexanet alfa off-label (if unavailable, use PCC or aPCC)
   • Consider activated charcoal if ingestion within 2-4 hours 1

For Non-Major Vaginal Bleeding:

Stop the anticoagulant 1

• Provide local therapy/manual compression
• If on warfarin: consider 2-5 mg PO/IV vitamin K 1
• Do NOT administer reversal agents for DOACs in non-major bleeding 1
• Supportive care and volume resuscitation
• Stop antiplatelet agents if applicable

Gynecologic-Specific Considerations

The 2025 interdisciplinary guideline emphasizes that anticoagulation-related reproductive tract bleeding (AC-RTB) is extremely common, affecting 20-60% of menstruating individuals on anticoagulation 2. Key points:

• Heavy menstrual bleeding (HMB) occurs in:

  • 22-71% on warfarin 2
  • 19-30% of adolescents on anticoagulants 2
  • 60-87% on DOACs (TEAM-VTE study) 2

• DOAC-specific bleeding risks 2:

  • Rivaroxaban: Highest risk of HMB (43% in adolescents) 2, 3
  • Apixaban: Lower risk compared to rivaroxaban 2, 4
  • Edoxaban: Comparable or slightly lower than rivaroxaban 2
  • Dabigatran: Possibly lowest risk (6.2-12.5%) 2

Hormonal Treatment Options

Once bleeding is controlled, consider these therapies for ongoing management 2:

• Levonorgestrel intrauterine device (7.6% usage rate in studies)
• Oral progestins (7.6% usage rate)
• Combined hormonal contraceptives (with caution due to thrombotic risk)

Critical caveat: Only 12.2% of patients with AC-RTB receive any pharmacologic therapy for bleeding, indicating significant undertreatment 5.

When to Resume Anticoagulation

After bleeding is controlled, delay restarting if any of these apply 1:

• Source of bleeding not yet identified
• High risk of rebleeding or death/disability with rebleeding
• Surgical/invasive procedures planned
• Patient preference to delay

Restart anticoagulation if none of the above factors apply and there remains a clinical indication for continued anticoagulation 1.

Multidisciplinary Approach Required

Coordinate care between hematology and gynecology 2. The 2025 guideline strongly emphasizes that managing vaginal bleeding on anticoagulation requires close interdisciplinary collaboration, as balancing bleeding and clotting risk demands nuanced decision-making 2, 5.

Common Pitfalls to Avoid

1. Continuing anticoagulation during major bleeding - Always stop for major bleeds 1
2. Using reversal agents for non-major bleeding - Reserve for life-threatening situations only 1
3. Failing to screen for underlying gynecologic pathology - Uterine fibroids significantly worsen bleeding (5 vs 4 mean unplanned visits) 4
4. Not considering DOAC switching - If on rivaroxaban with problematic bleeding, consider switching to apixaban which has lower bleeding risk 2, 4
5. Premature anticoagulation cessation - 29.5% require transfusion and 10.5% have ED visits, but anticoagulation may still be necessary 5